State of Wyoming Acquires Shares of 16,379 Septerna, Inc. $SEPN

State of Wyoming acquired a new position in shares of Septerna, Inc. (NASDAQ:SEPN) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 16,379 shares of the company’s stock, valued at approximately $549,000.

Several other institutional investors and hedge funds have also made changes to their positions in SEPN. Goldman Sachs Group Inc. boosted its position in shares of Septerna by 86.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after purchasing an additional 1,260,409 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of Septerna in the first quarter valued at approximately $21,334,000. First Light Asset Management LLC purchased a new position in shares of Septerna during the fourth quarter worth approximately $17,308,000. Primecap Management Co. CA acquired a new position in shares of Septerna in the 4th quarter valued at $15,225,000. Finally, Perceptive Advisors LLC purchased a new stake in Septerna in the 2nd quarter valued at $5,723,000.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research report on Friday, July 17th. Raymond James Financial reissued a “strong-buy” rating and set a $49.00 price target on shares of Septerna in a report on Tuesday, August 11th. Truist Financial boosted their target price on Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Wells Fargo & Company increased their price target on shares of Septerna from $48.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Finally, Stifel Nicolaus set a $49.00 price objective on Septerna in a report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Septerna presently has a consensus rating of “Moderate Buy” and an average price target of $51.33.

Septerna Price Performance

Shares of SEPN opened at $44.20 on Tuesday. Septerna, Inc. has a 1-year low of $10.74 and a 1-year high of $51.10. The firm has a 50 day simple moving average of $36.11 and a 200-day simple moving average of $29.80. The stock has a market cap of $2.06 billion, a price-to-earnings ratio of -81.85 and a beta of 2.29.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, August 10th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14. The firm had revenue of $26.75 million for the quarter, compared to analysts’ expectations of $19.22 million. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. On average, equities analysts expect that Septerna, Inc. will post -1.36 earnings per share for the current fiscal year.

Insider Activity at Septerna

In other Septerna news, COO Elizabeth Bhatt sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $44.00, for a total transaction of $1,100,000.00. Following the sale, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at $7,665,196. This trade represents a 12.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Daniel D. Long sold 3,334 shares of Septerna stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $34.47, for a total transaction of $114,922.98. Following the sale, the senior vice president owned 96,412 shares of the company’s stock, valued at approximately $3,323,321.64. This trade represents a 3.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 72,828 shares of company stock valued at $2,684,314 over the last quarter. Insiders own 5.80% of the company’s stock.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.